CIRC's Self-Developed Erythrocyte Lifespan Breath Analyzer Secures Medical Device Registration

Stock News
03/02

CIRC (01763) announced that its subsidiary, Anhui Yanghe Medical Equipment Co., Ltd., under Zhonghe Haidewei, has obtained a Class II medical device registration certificate for its self-developed "Erythrocyte Lifespan Determination Breath Analyzer." The approval for market launch signifies a major advancement for CIRC beyond its established expertise in Helicobacter pylori breath testing, marking its official entry into the new field of erythrocyte lifespan detection through breath analysis. This development is expected to promote the application of breath testing technology in early screening and clinical diagnosis of hematological diseases.

Clinically, erythrocyte lifespan measurement is primarily used for diagnosing anemia and hemolysis. Accelerated destruction of red blood cells can lead to hemolytic anemia, with symptoms such as fatigue, pallor, and jaundice. Measuring erythrocyte lifespan helps identify the underlying cause. It also aids in differentiating the origin of jaundice—whether due to excessive red blood cell breakdown or liver issues—in both newborns and adults, enabling quicker medical assessment. Additionally, for patients with diagnosed blood disorders, regular erythrocyte lifespan testing can evaluate treatment efficacy and monitor disease recurrence.

The analyzer operates on the principle of endogenous carbon monoxide (CO) metabolism detection. By analyzing the concentration of trace CO in exhaled breath, it scientifically calculates erythrocyte lifespan, enabling non-invasive quantitative assessment. A single test takes approximately 250 seconds to generate a report, significantly improving detection efficiency and accuracy, making it suitable for use in clinical departments such as hematology.

The device integrates testing procedures, data management, and equipment maintenance into a unified system, enhancing operational stability and user-friendliness. It meets clinical demands by simplifying operation for healthcare professionals, utilizing technological innovation to safeguard respiratory health.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10